ScholarLens Back to search
2002•Unpublished venueRequires access

Reverse effect of losartan on myocardial fibrosis and left ventricular hypertrophy in treatment of essential hypertensive patients

Lin Wen

Open publisher page 0 citations

Abstract

AIM: To investigate the effects of losartan on myocardial fibrosis and left ventricular hypertrophy in hypertensive patients. METHODS: 35 essential hypertensive patients with left ventricular hypertrophy were treated with losartan 50-100 mg for 6 mon. Before and after the treatment, serum procollagen typeⅢ (PCⅢ), laminin (LN), and hyaluronic acid (HA) were measured by radioimmunoassay; and left ventricular mass index (LVMI) was determined with ultrasonic cardiogram. RESULTS: After treatment with losartan: the serum levels of PCⅢ, LN, HA, and LVMI were all decreased (P0.05 or P0.01), and the blood pressure was also decreased significantly (P0.01). CONCLUSION: Losartan can decrease blood pressure, and reverse the left ventricular hypertrophy and myocardial fibrosis in hypertensive patients.

About this research paper

What this paper is about

AIM: To investigate the effects of losartan on myocardial fibrosis and left ventricular hypertrophy in hypertensive patients. METHODS: 35 essential hypertensive patients with left ventricular hypertrophy were treated with losartan 50-100 mg for 6 mon. Before and after the treatment, serum procollagen typeⅢ (PCⅢ), laminin (LN), and hyaluronic acid (HA) were measured by radioimmunoassay; and left ventricular mass index (LVMI) was determined with ultrasonic cardiogram. RESULTS: After treatment with losartan: the serum levels of PCⅢ, LN, HA, and LVMI were all decreased (P0.05 or P0.01), and the blood pressure was also decreased significantly (P0.01). CONCLUSION: Losartan can decrease blood pressure, and reverse the left ventricular hypertrophy and myocardial fibrosis in hypertensive patients.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

AIM: To investigate the effects of losartan on myocardial fibrosis and left ventricular hypertrophy in hypertensive patients. METHODS: 35 essential hypertensive patients with left ventricular hypertrophy were treated with losartan 50-100 mg for 6 mon. Before and after the treatment, serum procollagen typeⅢ (PCⅢ), laminin (LN), and hyaluronic acid (HA) were measured by radioimmunoassay; and left ventricular mass index (LVMI) was determined with ultrasonic cardiogram. RESULTS: After treatment with losartan: the serum levels of PCⅢ, LN, HA, and LVMI were all decreased (P0.05 or P0.01), and the blood pressure was also decreased significantly (P0.01). CONCLUSION: Losartan can decrease blood pressure, and reverse the left ventricular hypertrophy and myocardial fibrosis in hypertensive patients.

Key concepts: Losartan, Medicine, Left ventricular hypertrophy, Internal medicine, Cardiology, Myocardial fibrosis, Fibrosis, Blood pressure

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Reverse effect of losartan on myocardial fibrosis and left ventricular hypertrophy in treatment of essential hypertensive patients — Research Paper | ScholarLens